Does Guanfacine Attenuate Stress-Induced Drinking?

Completed · Phase 2 · Has a placebo group

Conditions studied: Alcohol Drinking

In brief

Evaluating the effect of guanfacine on alcohol consumption. The investigators hypothesize that guanfacine versus placebo will decrease the amount of alcohol consumption (mls consumed) during the 2-hour self-administration period across two laboratory sessions.

Key facts

Study ID

NCT02164422

Run by

Yale University

People needed

70

Starts

2014-06-01

Expected to finish

2020-03-31

Last updated by the study team

2021-07-08

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 21-65
• Able to read and write English
• Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for current (past 6 months) alcohol abuse or alcohol dependence

You may not qualify if…

• Participants with any significant current medical conditions, seizures, delirium or hallucinations, or other unstable medical conditions including HIV
• Current DSM-IV abuse or dependence on substances, other than alcohol abuse, alcohol dependence, or nicotine dependence
• Women who are pregnant or nursing
• Suicidal, homicidal or evidence of current (past 6-month) mental illness
• Meet DSM-IV criteria for current (past-6 month) attention deficit hyperactivity disorder (ADHD)
• Specific exclusions for administration of guanfacine not already specified include: EKG evidence at baseline screening of any clinically significant conduction abnormalities or arrhythmias; known intolerance for guanfacine or any alpha blocker; history of fainting, syncopal attacks, heart failure or myocardial infarction, or impaired liver as indicated by aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 3x normal or renal function (estimated creatinine clearance <60 cc/min); treatment with any antihypertensive drug or any alpha-adrenergic blocker; use of any central nervous system (CNS) depressant (e.g., phenothiazines, barbiturates, benzodiazepines)
• Subjects likely to exhibit clinically significant alcohol withdrawal during the study.
• Individuals who are seeking treatment for drinking

Where it is running

• Yale Center for Clinical Investigations, Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.